BL153 partially prevents high-fat diet induced liver damage probably via inhibition of lipid accumulation, inflammation, and oxidative stress

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Wang, Jian ^a,b,c   Zhang, Chi ^b,d   Zhang, Zhiguo ^c,e   Chen, Qiang ^c,e   Lu, Xuemian ^b,d   Shao, Minglong ^b,d   Chen, Liangmiao ^b,d   Yang, Hong ^b,d   Zhang, Fangfang ^b,d   Cheng, Peng ^b,d   Tan, Yi ^b,c   Kim, Ki Soo ^f   Kim, Ki Ho ^g   Wang, Bochu ^a   Kim, Young Heui ^g  

^a CHONGQING UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c University of Louisville School of Medicine   (United States)

^d THE THIRD AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^e JILIN UNIVERSITY   (China)

^f Bioland Biotec Co Ltd Zhangjiang Modern Medical Device Park   (China)

^g Bioland Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHROPOMETRY; COLLAGEN; MAMMALS; MUSCULOSKELETAL SYSTEM; OXIDATIVE STRESS; PATHOLOGY;

AGE-MATCHED CONTROLS; CONNECTIVE TISSUE GROWTH FACTOR; CRITICAL STEPS; DOSE-DEPENDENT MANNER; HEPATIC FIBROSIS; LIPID ACCUMULATIONS; MECHANISM STUDIES; TRANSFORMING GROWTH FACTOR BETA;

NUTRITION;

BL153 EXTRACT; CONNECTIVE TISSUE GROWTH FACTOR; PLANT EXTRACT; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; BODY WEIGHT; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; INFLAMMATION; LIPID DIET; LIPID METABOLISM; LIVER; MAGNOLIA; MALE; METABOLISM; MOUSE; OBESITY; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; BODY WEIGHT; CONNECTIVE TISSUE GROWTH FACTOR; DIET, HIGH-FAT; INFLAMMATION; LIPID METABOLISM; LIVER; MAGNOLIA; MALE; MICE; MICE, INBRED C57BL; OBESITY; OXIDATIVE STRESS; PLANT EXTRACTS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84899578421     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/674690     Document Type: Article

References (51)

1. Poirier P., Targeting abdominal obesity in cardiology: can we be effective? The Canadian Journal of Cardiology 2008 24 supplement D 13D 17D 2-s2.0-55949127411
2. Ogden C. L., Yanovski S. Z., Carroll M. D., Flegal K. M., The epidemiology of obesity. Gastroenterology 2007 132 6 2087 2102 2-s2.0-34247851021 10.1053/j.gastro.2007.03.052 (Pubitemid 46693751)
3. Lin Z., Zhou Z., Liu Y., Gong Q., Yan X., Xiao J., Wang X., Lin S., Feng W., Li X., Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS ONE 2011 6 4 2-s2.0-79954525448 10.1371/journal.pone.0018398 e18398
4. Farrell G. C., Larter C. Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006 43 2 supplement 1 S99 S112 2-s2.0-33644547706 10.1002/hep.20973
5. Adams L. A., Lymp J. F., St. Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P., The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 129 1 113 121 2-s2.0-22344452893 10.1053/j.gastro.2005.04.014 (Pubitemid 41002048)
6. Dowman J. K., Tomlinson J. W., Newsome P. N., Pathogenesis of non-alcoholic fatty liver disease. QJM 2010 103 2 71 83 2-s2.0-77950323927 10.1093/qjmed/hcp158
7. Tacer K. F., Rozman D., Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. Journal of Lipids 2011 2011 14 783976 10.1155/2011/783976
8. Day C. P., James O. F. W., Steatohepatitis: a tale of two "hits"? Gastroenterology 1998 114 4 842 845 2-s2.0-0031947715 10.1016/S0016-5085(98)70599-2 (Pubitemid 28160420)
9. Kuribara H., Kishi E., Hattori N., Okada M., Maruyama Y., The anxiolytic effect of two oriental herbal drugs in Japan attributed to honokiol from magnolia bark. Journal of Pharmacy and Pharmacology 2000 52 11 1425 1429 2-s2.0-0033652218 10.1211/0022357001777432
10. Li Y., Xu C., Zhang Q., Liu J. Y., Tan R. X., In vitro anti- Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. Journal of Ethnopharmacology 2005 98 3 329 333 2-s2.0-16244405307 10.1016/j.jep.2005.01.020 (Pubitemid 40461989)
11. Bajpai V. K., Yoon J. I., Kang S. C., Antioxidant and antidermatophytic activities of essential oil and extracts of Magnolia liliflora Desr. Food and Chemical Toxicology 2009 47 10 2606 2612 2-s2.0-69549121609 10.1016/j.fct.2009. 07.025
12. Dikalov S., Losik T., Arbiser J. L., Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochemical Pharmacology 2008 76 5 589 596 2-s2.0-49149119432 10.1016/j.bcp.2008.06.012
13. Ock J., Han H. S., Hong S. H., Lee S. Y., Han Y.-M., Kwon B.-M., Suk K., Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. British Journal of Pharmacology 2010 159 8 1646 1662 2-s2.0-77950202753 10.1111/j.1476-5381.2010.00659.x
14. Lin Y.-R., Chen H.-H., Ko C.-H., Chan M.-H., Effects of honokiol and magnolol on acute and inflammatory pain models in mice. Life Sciences 2007 81 13 1071 1078 2-s2.0-34548699687 10.1016/j.lfs.2007.08.014 (Pubitemid 47418846)
15. Munroe M. E., Arbiser J. L., Bishop G. A., Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. The Journal of Immunology 2007 179 2 753 763 2-s2.0-34548764511
16. Grivennikov S. I., Karin M., Dangerous liaisons: STAT3 and NF- B collaboration and crosstalk in cancer. Cytokine and Growth Factor Reviews 2010 21 1 11 19 2-s2.0-77549083560 10.1016/j.cytogfr.2009.11.005
17. Karin M., NF- B and cancer: mechanisms and targets. Molecular Carcinogenesis 2006 45 6 355 361 10.1002/mc.20217 (Pubitemid 43865841)
18. Park E.-J., Kim S.-Y., Zhao Y.-Z., Sohn D. H., Honokiol reduces oxidative stress, c-jun-NH2-terminal kinase phosphorylation and protects against glycochenodeoxycholic acid-induced apoptosis in primary cultured rat hepatocytes. Planta Medica 2006 72 7 661 664 2-s2.0-33745712237 10.1055/s-2006-931571
19. Choi M. S., Lee S. H., Cho H. S., Kim Y., Yun Y. P., Jung H. Y., Jung J. K., Lee B. C., Pyo H. B., Hong J. T., Inhibitory effect of obovatol on nitric oxide production and activation of NF- B/MAP kinases in lipopolysaccharide- treated RAW 264.7cells. European Journal of Pharmacology 2007 556 1-3 181 189 2-s2.0-33846260180 10.1016/j.ejphar.2006.10.054 (Pubitemid 46098933)
20. Ou H.-C., Chou F.-P., Sheu W. H.-H., Hsu S.-L., Lee W.-J., Protective effects of magnolol against oxidized LDL-induced apoptosis in endothelial cells. Archives of Toxicology 2007 81 6 421 432 2-s2.0-34250821328 10.1007/s00204-006-0172-3 (Pubitemid 46980505)
21. Chiang C.-K., Sheu M.-L., Lin Y.-W., Wu C.-T., Yang C.-C., Chen M.-W., Hung K.-Y., Wu K.-D., Liu S.-H., Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro. British Journal of Pharmacology 2011 163 3 586 597 2-s2.0-79955888192 10.1111/j.1476-5381.2011.01242.x
22. Chiu J.-H., Wang J.-C., Lui W.-Y., Wu C.-W., Hong C.-Y., Effect of magnolol on in vitro mitochondrial lipid peroxidation and isolated cold-preserved warm-reperfused rat livers. Journal of Surgical Research 1999 82 1 11 16 2-s2.0-0032865634 10.1006/jsre.1998.5455 (Pubitemid 29394146)
23. Lin M. H., Chao H. T., Hong C. Y., Magnolol protects human sperm motility against lipid peroxidation: a sperm head fixation method. Archives of Andrology 1995 34 3 151 156 2-s2.0-0029047074 10.3109/01485019508987843
24. Cui W., Wang Y., Chen Q., Sun W., Cai L., Tan Y., Kim K. -S., Kim K. H., Kim Y. H., Magnolia extract (BL153) ameliorates kidney damage in a high fat diet-induced obesity mouse model. Oxidative Medicine and Cellular Longevity 2013 2013 9 367040 10.1155/2013/367040
25. Lee Y. K., Yuk D. Y., Kim T. I., Kim Y. H., Kim K. T., Kim K. H., Lee B. J., Nam S.-Y., Hong J. T., Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. Journal of Natural Medicines 2009 63 3 274 282 2-s2.0-67650747670 10.1007/s11418-009-0330-z
26. Lee Y.-J., Lee Y. M., Lee C.-K., Jung J. K., Han S. B., Hong J. T., Therapeutic applications of compounds in the Magnolia family. Pharmacology and Therapeutics 2011 130 2 157 176 2-s2.0-79953654775 10.1016/j.pharmthera.2011.01. 010
27. Song Y., Li C., Cai L., Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Experimental and Molecular Pathology 2004 76 1 66 75 2-s2.0-0346040260 10.1016/j.yexmp.2003.08.002 (Pubitemid 38096321)
28. Zhou G., Li C., Cai L., Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β -independent pathway. The American Journal of Pathology 2004 165 6 2033 2043 2-s2.0-9644284528 10.1016/S0002-9440(10)63254-3 (Pubitemid 39578381)
29. Zhang C., Tan Y., Guo W., Li C., Ji S., Li X., Cai L., Attenuation of diabetes-induced renal dysfunction by multiple exposures to low-dose radiation is associated with the suppression of systemic and renal inflammation. The American Journal of Physiology-Endocrinology and Metabolism 2009 297 6 E1366 E1377 2-s2.0-72249109610 10.1152/ajpendo.00478.2009
30. Faria S. C., Ganesan K., Mwangi I., Shiehmorteza M., Viamonte B., Mazhar S., Peterson M., Kono Y., Santillan C., Casola G., Sirlin C. B., MR imaging of liver fibrosis: current state of the art. Radiographics 2009 29 6 1615 1635 2-s2.0-77449088122 10.1148/rg.296095512
31. Rockey D. C., Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008 134 1 8 14 2-s2.0-37349090047 10.1053/j.gastro.2007.11.053 (Pubitemid 350309358)
32. Choong C. C., Venkatesh S. K., Siew E. P., Accuracy of routine clinical ultrasound for staging of liver fibrosis. Journal of Clinical Imaging Science 2012 2 article 58 10.4103/2156-7514.101000
33. Nobili V., Alisi A., Vania A., Tiribelli C., Pietrobattista A., Bedogni G., The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Medicine 2009 7, article 21 2-s2.0-66149168706 10.1186/1741-7015-7-21
34. Sass D. A., Chang P., Chopra K. B., Nonalcoholic fatty liver disease: a clinical review. Digestive Diseases and Sciences 2005 50 1 171 180 2-s2.0-14544308375 10.1007/s10620-005-1267-z (Pubitemid 40379159)
35. Kawano Y., Cohen D. E., Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. Journal of Gastroenterology 2013 48 4 434 441 10.1007/s00535-013-0758-5
36. Yao H.-R., Liu J., Plumeri D., Cao Y.-B., He T., Lin L., Li Y., Jiang Y.-Y., Li J., Shang J., Lipotoxicity in HepG2 cells triggered by free fatty acids. The American Journal of Translational Research 2011 3 3 284 291 2-s2.0-79957561550
37. Goldfine A. B., Silver R., Aldhahi W., Cai D., Tatro E., Lee J., Shoelson S. E., Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clinical and Translational Science 2008 1 1 36 43 2-s2.0-64149121817 10.1111/j.1752-8062.2008.00026.x
38. Shoelson S. E., Herrero L., Naaz A., Obesity, inflammation, and insulin resistance. Gastroenterology 2007 132 6 2169 2180 2-s2.0-34247857663 10.1053/j.gastro.2007.03.059 (Pubitemid 46693756)
39. Shoelson S. E., Lee J., Goldfine A. B., Inflammation and insulin resistance. Journal of Clinical Investigation 2006 116 7 1793 1801 2-s2.0-33745861300 10.1172/JCI29069
40. Fernandez-Sanchez A., Madrigal-Santillan E., Bautista M., Esquivel-Soto J., Morales-González A., Esquivel-Chirino C., Durante-Montiel I., Sánchez-Rivera G., Valadez-Vega C., Morales-González J. A., Inflammation, oxidative stress, and obesity. International Journal of Molecular Sciences 2011 12 5 3117 3132 10.3390/ijms12053117
41. Xu H., Barnes G. T., Yang Q., Tan G., Yang D., Chou C. J., Sole J., Nichols A., Ross J. S., Tartaglia L. A., Chen H., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 2003 112 12 1821 1830 2-s2.0-9144223683 10.1172/JCI200319451 (Pubitemid 38063705)
42. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I., Increased oxidative stress in obesity and its impact on metabolic syndrome. Journal of Clinical Investigation 2004 114 12 1752 1761 2-s2.0-15244342531 10.1172/JCI200421625 (Pubitemid 40385531)
43. Machado M., Marques-Vidal P., Cortez-Pinto H., Hepatic histology in obese patients undergoing bariatric surgery. Journal of Hepatology 2006 45 4 600 606 2-s2.0-33748110788 10.1016/j.jhep.2006.06.013 (Pubitemid 44307393)
44. Rector R. S., Thyfault J. P., Wei Y., Ibdah J. A., Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World Journal of Gastroenterology 2008 14 2 185 192 2-s2.0-39849099669 10.3748/wjg.14.185 (Pubitemid 351314297)
45. Lazo M., Clark J. M., The epidemiology of nonalcoholic fatty liver disease: a global perspective. Seminars in Liver Disease 2008 28 4 339 350 2-s2.0-56649123256 10.1055/s-0028-1091978
46. Day C. P., From fat to inflammation. Gastroenterology 2006 130 1 207 210 2-s2.0-30044431801 10.1053/j.gastro.2005.11.017 (Pubitemid 43049850)
47. Wang S.-M., Lee L.-J., Huang Y.-T., Chen J.-J., Chen Y.-L., Magnolol stimulates steroidogenesis in rat adrenal cells. British Journal of Pharmacology 2000 131 6 1172 1178 2-s2.0-0033680196 10.1038/sj.bjp.0703669
48. Crum-Cianflone N., Dilay A., Collins G., Asher D., Campin R., Medina S., Goodman Z., Parker R., Lifson A., Capozza T., Bavaro M., Hale B., Hames C., Nonalcoholic fatty liver disease among HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes 2009 50 5 464 473 2-s2.0-65449180351 10.1097/QAI.0b013e318198a88a
49. Lewis M. C., Phillips M. L., Slavotinek J. P., Kow L., Thompson C. H., Toouli J., Change in liver size and fat content after treatment with Optifast very low calorie diet. Obesity Surgery 2006 16 6 697 701 2-s2.0-33745018473 10.1381/096089206777346682 (Pubitemid 43874822)
50. Ho J. H., Hong C. Y., Cardiovascular protection of magnolol: cell-type specificity and dose-related effects. Journal of Biomedical Science 2012 19 article 70 10.1186/1423-0127-19-70
51. Li J., Shao X., Wu L., Feng T., Jin C., Fang M., Wu N., Yao H., Honokiol: an effective inhibitor of tumor necrosis factor- α -induced up-regulation of inflammatory cytokine and chemokine production in human synovial fibroblasts. Acta Biochimica et Biophysica Sinica 2011 43 5 380 386 2-s2.0-79955395053 10.1093/abbs/gmr027